These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34524004)

  • 1. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhao J; He M; Li J; Li D; Zhao Y; Li X; Zhang X; Chen X; Liu Y; Zhao L
    Cancer Biother Radiopharm; 2022 May; 37(4):324-331. PubMed ID: 34524004
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
    Qin J; Xue L; Hao A; Guo X; Jiang T; Ni Y; Liu S; Chen Y; Jiang H; Zhang C; Kang M; Lin J; Li H; Li C; Tian H; Li L; Fu J; Zhang Y; Ma J; Wang X; Fu M; Yang H; Yang Z; Han Y; Chen L; Tan L; Dai T; Liao Y; Zhang W; Li B; Chen Q; Guo S; Qi Y; Wei L; Li Z; Tian Z; Kang X; Zhang R; Li Y; Wang Z; Chen X; Hou Z; Zheng R; Zhu W; He J; Li Y
    Nat Med; 2024 Sep; 30(9):2549-2557. PubMed ID: 38956195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
    Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
    BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial.
    Yang B; Guo X; Le C; Su W; Li X; Zhang Y; Yang G; Liang W; Zheng Z; Wu J; Zhang Y; Hao A
    Biomed Res Int; 2022; 2022():4727407. PubMed ID: 35898681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
    Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
    Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
    Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
    Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
    Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
    Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
    Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery.
    Li C; Yu P; Li H; Yang X; Wang J; Jiang B
    J Cardiothorac Surg; 2024 Jan; 19(1):26. PubMed ID: 38273405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.
    Zheng Y; Liang G; Yuan D; Liu X; Ba Y; Qin Z; Shen S; Li Z; Sun H; Liu B; Gao Q; Li P; Wang Z; Liu S; Zhu J; Wang H; Ma H; Liu Z; Zhao F; Zhang J; Zhang H; Wu D; Qu J; Ma J; Zhang P; Ma W; Yan M; Yu Y; Li Q; Zhang J; Xing W
    Cancer Commun (Lond); 2024 Oct; 44(10):1214-1227. PubMed ID: 39221992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
    Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
    Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
    Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
    EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
    Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
    Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study.
    Wang J; Zhang J; Gao J; Zhao M; Ma Z
    Adv Clin Exp Med; 2024 Jun; 33(6):573-581. PubMed ID: 37676100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.